SEC Form 4 · accession 0001562180-16-002697
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M Frates
Director
Period of report
Jun 22, 2016
Accepted (ET)
Jun 24, 2016 · 11:34 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F1 | $28.35 | Jun 22, 2016 | A | 13,922 | A | — | Jun 22, 2026 | Common Stock | 13,922 | 13,922 | D |
Explanation of responses
- F1The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option shall vest in full on June 22, 2017, subject to continued service through such date.